HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lawsuit Seeking FDA Triclosan Action Stays Alive On Appeal

This article was originally published in The Rose Sheet

Executive Summary

A court ruling allowing an advocacy group to move forward in its suit against FDA could pave the way for future litigation intended to force the agency to complete delayed regulations.

You may also be interested in...



New “Seriously Friendly” Oral-Care Brand Says Hello

Investors convinced that Hello Products can shake up the oral-care market back the firm’s launch of “the first-ever seriously friendly oral-care brand for consumers.”

U.S. Sunscreen Group Suggests User Fees To Expedite Ingredient Reviews

The Public Access to SunScreens Coalition will recommend a user-fee program to improve FDA’s work on TEAs for OTC ingredients. “Despite a number of OTC applications waiting for approval for several years, FDA has not completed the review of applications for any new sunscreen components,” PASS says.

Rep. Markey Calls For Triclosan Ban, Galvanized By Sympathetic FDA Letter

Rep. Ed Markey, D-Mass., wants many personal-care applications of triclosan banned and is crafting chemicals safety legislation after receiving letters from FDA and EPA acknowledging that there are concerns about the ingredient

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel